Valeria Cernaro1, Silvia Lucisano1, Valeria Canale1, Annamaria Bruzzese1, Daniela Caccamo2, Giuseppe Costantino1, Michele Buemi1, Domenico Santoro3. 1. Department of Clinical and Experimental Medicine, University of Messina, AOU G. Martino PAD C, Via Consolare Valeria, 98100, Messina, Italy. 2. Department of Biomedical Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy. 3. Department of Clinical and Experimental Medicine, University of Messina, AOU G. Martino PAD C, Via Consolare Valeria, 98100, Messina, Italy. santisi@hotmail.com.
Abstract
AIM: Serum levels of 32 kDa-phosphaturic hormone fibroblast growth factor 23 (FGF23) rise early in renal failure in order to keep phosphatemia within the normal range; however, this compensatory mechanism itself contributes to chronic kidney disease-mineral bone disorder. High FGF23 is also associated to left ventricular hypertrophy, vascular calcifications and thus increased cardiovascular risk. The aim of this pilot pre-post study was to evaluate the effects of a single hemodiafiltration session with acetate-free biofiltration (AFB) on FGF23 serum levels. METHODS: Nine hemodialysis patients were enrolled; sessions were performed using the Integra® monitor (Hospal, Bologna, Italy) and a polyacrylonitrile membrane. Peripheral venous blood samples were taken before (pre-HD), at mid- and after treatment (post-HD); dialysate samples were collected by the Quantiscan™ monitoring system. FGF23 was measured by a human FGF-23 ELISA kit. Mid- and post-HD values were corrected for hemoconcentration. RESULTS: Pre-HD FGF23 levels positively correlated with dialysis vintage (r = 0.7192; p = 0.0443). They were significantly reduced by the hemodialysis session (from 2.38 ± 1.80 to 1.15 ± 1.21 ng/ml, p = 0.0171) with a reduction ratio of 52.55 ± 28.76%. FGF23 was detected in the dialysate samples. CONCLUSION: FGF23 underwent a significant reduction during AFB. Such removal was greater than that induced by conventional hemodialysis as reported in the literature (19%-decrease using modified cellulosic membranes). This difference may be attributed to the ability of AFB hemodiafiltration to efficiently remove middle molecules by convection. Whether a better clearance of FGF23 during hemodialysis may result in improved cardiovascular outcomes in the long term needs to be confirmed by randomized controlled trials.
AIM: Serum levels of 32 kDa-phosphaturic hormone fibroblast growth factor 23 (FGF23) rise early in renal failure in order to keep phosphatemia within the normal range; however, this compensatory mechanism itself contributes to chronic kidney disease-mineral bone disorder. High FGF23 is also associated to left ventricular hypertrophy, vascular calcifications and thus increased cardiovascular risk. The aim of this pilot pre-post study was to evaluate the effects of a single hemodiafiltration session with acetate-free biofiltration (AFB) on FGF23 serum levels. METHODS: Nine hemodialysis patients were enrolled; sessions were performed using the Integra® monitor (Hospal, Bologna, Italy) and a polyacrylonitrile membrane. Peripheral venous blood samples were taken before (pre-HD), at mid- and after treatment (post-HD); dialysate samples were collected by the Quantiscan™ monitoring system. FGF23 was measured by a humanFGF-23 ELISA kit. Mid- and post-HD values were corrected for hemoconcentration. RESULTS: Pre-HDFGF23 levels positively correlated with dialysis vintage (r = 0.7192; p = 0.0443). They were significantly reduced by the hemodialysis session (from 2.38 ± 1.80 to 1.15 ± 1.21 ng/ml, p = 0.0171) with a reduction ratio of 52.55 ± 28.76%. FGF23 was detected in the dialysate samples. CONCLUSION:FGF23 underwent a significant reduction during AFB. Such removal was greater than that induced by conventional hemodialysis as reported in the literature (19%-decrease using modified cellulosic membranes). This difference may be attributed to the ability of AFB hemodiafiltration to efficiently remove middle molecules by convection. Whether a better clearance of FGF23 during hemodialysis may result in improved cardiovascular outcomes in the long term needs to be confirmed by randomized controlled trials.
Authors: Raymond Vanholder; Rita De Smet; Griet Glorieux; Angel Argilés; Ulrich Baurmeister; Philippe Brunet; William Clark; Gerald Cohen; Peter Paul De Deyn; Reinhold Deppisch; Beatrice Descamps-Latscha; Thomas Henle; Achim Jörres; Horst Dieter Lemke; Ziad A Massy; Jutta Passlick-Deetjen; Mariano Rodriguez; Bernd Stegmayr; Peter Stenvinkel; Ciro Tetta; Christoph Wanner; Walter Zidek Journal: Kidney Int Date: 2003-05 Impact factor: 10.612
Authors: A Santoro; G Panzetta; N Tessitore; M Atti; E Mancini; J Esteban; G London; J M Ara; J L Miguel; K H Neumann; K Opatrny; R Perez; B Perrone; V Wizemann; P Zucchelli Journal: J Nephrol Date: 1999 Nov-Dec Impact factor: 3.902
Authors: Tae Yamamoto; Marcelo M Nascimento; Shirley Y Hayashi; Abdul Rashid Qureshi; Jacek Waniewski; Lars Åke Brodin; Björn Anderstam; Britta Lind; Miguel C Riella; Astrid Seeberger; Bengt Lindholm Journal: Hemodial Int Date: 2012-06-20 Impact factor: 1.812
Authors: Maurizio Gallieni; Nicola De Luca; Domenico Santoro; Gina Meneghel; Marco Formica; Giuseppe Grandaliano; Francesco Pizzarelli; Maria Cossu; Giuseppe Segoloni; Giuseppe Quintaliani; Salvatore Di Giulio; Antonio Pisani; Moreno Malaguti; Cosimo Marseglia; Lamberto Oldrizzi; Mario Pacilio; Giuseppe Conte; Antonio Dal Canton; Roberto Minutolo Journal: J Nephrol Date: 2015-05-19 Impact factor: 3.902
Authors: Nicola Tessitore; Antonio Santoro; Giovanni Oliviero Panzetta; Volker Wizemann; Rafael Perez-Garcia; Jorge Martinez Ara; Bruno Perrone; William Mantovani; Albino Poli Journal: Blood Purif Date: 2013-02-12 Impact factor: 2.614
Authors: Jelmer K Humalda; Ineke J Riphagen; Solmaz Assa; Yoran M Hummel; Ralf Westerhuis; Marc G Vervloet; Adriaan A Voors; Gerjan Navis; Casper F M Franssen; Martin H de Borst Journal: Nephrol Dial Transplant Date: 2015-11-24 Impact factor: 5.992
Authors: Ting Jia; Abdul Rashid Qureshi; Vincent Brandenburg; Markus Ketteler; Peter Barany; Olof Heimburger; Fredrik Uhlin; Per Magnusson; Anders Fernström; Bengt Lindholm; Peter Stenvinkel; Tobias E Larsson Journal: Am J Nephrol Date: 2013-04-27 Impact factor: 3.754
Authors: Annet Bouma-de Krijger; Camiel L M de Roij van Zuijdewijn; Menso J Nubé; Muriel P C Grooteman; Marc G Vervloet Journal: Clin Kidney J Date: 2020-04-01